抗血管生成药物联合紫杉醇和顺铂在非小细胞肺癌中应用价值分析

doi:10.3969/j.issn.1671-7171.2021.07.033

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1177 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the application value of anti angiogenesis drugs combined with paclitaxel and cisplatin in non-small cell lung cancer(NSCLC).【Methods】A total of 80 patients with NSCLC in our hospital were selected and divided into control group(n=40, paclitaxel and cisplatin chemotherapy) and observation group(n=40, bevacizumab combined with paclitaxel and cisplatin chemotherapy) according to different treatment schemes. The clinical effective rate, changes of tumor markers and immune indexes, quality of life and adverse reactions of the two groups were compared. 【Results】The total effective rate of the observation group was 57.5%(23/40), which was higher than 25.00%(10/40) of the control group, and there was significant difference between the two groups(P<0.05); Carcinoembryonic antigen, vascular endothelial growth factor(VEGF) and basic fibroblast growth factor(bFGF) of the two groups were improved after treatment(P<0.05), and the observation group was better than the control group(P<0.05); After treatment, the levels of CD3⁺ CD4⁺ CD8⁺ CD4⁺/CD8⁺ in the observation group were higher than those before treatment(P<0.05); The levels of CD3⁺ CD4⁺ CD8⁺ in the control group were lower than those before treatment(P<0.05), and the indexes in the observation group were higher than those in the control group(P<0.05); The quality of life score of the observation group was(46. 81±7. 58) was higher than(38. 17 ±7. 29)(P<0.05); There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). 【Conclusion】 Anti angiogenic drugs combined with paclitaxel and cisplatin in the treatment of NSCLC has higher clinical efficacy and fewer adverse reactions, which can effectively improve the immune system damage, promote the recovery of tumor markers and improve the quality of life of patients.

Key words： Carcinoma, Non-Small-Cell Lung/DT Antineoplastic Agents/TU Taxoids/TU Carboplatin/TU

Received: 19 March 2021

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XIE Lin
	HUAI Bao-hua

Cite this article:

XIE Lin,HUAI Bao-hua. Application Value of Anti-angiogenesis Drugs Combined with Paclitaxel and Cisplatin in Non-small Cell Lung Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(7): 1075-1078.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2021.07.033 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2021/V38/I7/1075

[1] 汤井娇. 抗血管生成药物长期治疗致肿瘤侵袭转移相关机制的研究进展[J].中国肿瘤临床, 2016, 43(7):71-73.
[2] 赵卫刚, 胡世莲, 丁西平, 等. 吉西他滨联合顺铂与紫杉醇联合顺铂/卡铂治疗非小细胞肺癌疗效的系统评价[J].实用医学杂志, 2016, 32(9):1508-1511.
[3] 赵华叶, 李国辉, 戚姝娅, 等. 艾迪注射液联合紫杉醇和顺铂治疗中晚期非小细胞肺癌疗效和安全性的Meta分析[J].中国药房, 2016, 26(9):1210-1213.
[4] 陈刚, 邬冬强. 贝伐珠单抗注射液辅助治疗老年局部非小细胞肺癌的临床研究[J].中国临床药理学杂志, 2016, 32(21):1967-1970.
[5] 郑宣轩, 王慧娟, 张国伟, 等. 二线及以上应用贝伐珠单抗联合化疗治疗晚期非鳞非小细胞肺癌的疗效及安全性观察[J].中国肺癌杂志, 2018, 21(7):24-29.
[6] 储天晴, 陈姬华, 韩宝惠. 贝伐珠单抗治疗晚期非小细胞肺癌的研究进展[J].中华肿瘤杂志, 2018, 40(10):793-800.
[7] 陈良安. 规范中国晚期非小细胞肺癌抗血管生成治疗:晚期非小细胞肺癌抗血管生成药物治疗中国呼吸领域专家共识(2016年版)解读[J].中华结核和呼吸杂志, 2016, 39(11):835-836.
[8] 牛志成, 何东伟, 汪治宇. 抗血管生成药物联合免疫检查点抑制剂治疗恶性肿瘤的研究进展[J].中国肿瘤生物治疗杂志, 2019, 26(9):1012-1018.
[9] 张士放, 文艳梅, 陈红, 等. 靶向抗血管生成治疗非小细胞肺癌的研究进展[J].山东医药, 2017, 60(14):113-116.
[10] 韩睿, 何勇. 抗血管生成治疗在晚期NSCLC的应用与进展[J].重庆医学, 2018, 47(15):94-97.
[11] 石荟, 白冲. 晚期非小细胞肺癌抗血管生成药物治疗中国呼吸领域专家共识解读(2016年版)[J].中国实用内科杂志, 2017,36(2):44-48.
[12] 昂冰, 武乐, 周彩云. 贝伐珠单抗联合顺铂治疗肺癌恶性胸水的临床疗效[J].中国肿瘤生物治疗杂志, 2018, 25(11):94-97.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(9): 1410-1412.